WO2013029062A1 - Conjugués lambda 1 d'interféron peg, leurs procédés de préparation, compositions pharmaceutiques contenant ces conjugués et leurs procédés de fabrication - Google Patents

Conjugués lambda 1 d'interféron peg, leurs procédés de préparation, compositions pharmaceutiques contenant ces conjugués et leurs procédés de fabrication Download PDF

Info

Publication number
WO2013029062A1
WO2013029062A1 PCT/VN2011/000009 VN2011000009W WO2013029062A1 WO 2013029062 A1 WO2013029062 A1 WO 2013029062A1 VN 2011000009 W VN2011000009 W VN 2011000009W WO 2013029062 A1 WO2013029062 A1 WO 2013029062A1
Authority
WO
WIPO (PCT)
Prior art keywords
peg
ιρνλι
conjugates
pharmaceutical composition
conjugate
Prior art date
Application number
PCT/VN2011/000009
Other languages
English (en)
Inventor
Nhan HO
Original Assignee
Nanogen Pharmaceutical Biotechnology Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanogen Pharmaceutical Biotechnology Co., Ltd filed Critical Nanogen Pharmaceutical Biotechnology Co., Ltd
Publication of WO2013029062A1 publication Critical patent/WO2013029062A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne de nouveaux conjugués lambda 1 d'interféron PEG (peg-ΓΡΝλΙ), leurs procédés de préparation, des compositions pharmaceutiques contenant ces conjugués et leurs procédés de fabrication. Ces conjugués possèdent un temps de persistance et des demi-vies dans le sang accrus par rapport à IFNλl et sont efficaces dans le traitement de l'hépatite B et de l'hépatite C.
PCT/VN2011/000009 2011-08-25 2011-11-15 Conjugués lambda 1 d'interféron peg, leurs procédés de préparation, compositions pharmaceutiques contenant ces conjugués et leurs procédés de fabrication WO2013029062A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
VN1-2011-0222 2011-08-25
VN201100222 2011-08-25

Publications (1)

Publication Number Publication Date
WO2013029062A1 true WO2013029062A1 (fr) 2013-02-28

Family

ID=47746931

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/VN2011/000009 WO2013029062A1 (fr) 2011-08-25 2011-11-15 Conjugués lambda 1 d'interféron peg, leurs procédés de préparation, compositions pharmaceutiques contenant ces conjugués et leurs procédés de fabrication

Country Status (1)

Country Link
WO (1) WO2013029062A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070071721A1 (en) * 2002-10-23 2007-03-29 Zymogenetics, Inc. Methods for treating viral infection using il-28 and il-29
US7351689B2 (en) * 2004-07-29 2008-04-01 Zymogenetics, Inc. Use of IL-28 and IL-29 to treat cancer and autoimmune disorders
US7727518B2 (en) * 2003-08-07 2010-06-01 Zymogenetics, Llc Method of using IL-29 cysteine mutant to treat hepatitis C and hepatitis B
US20110165121A1 (en) * 2008-06-05 2011-07-07 Hausman Diana F Use of pegylated type iii interferons for the treatment of hepatitis c

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070071721A1 (en) * 2002-10-23 2007-03-29 Zymogenetics, Inc. Methods for treating viral infection using il-28 and il-29
US7727518B2 (en) * 2003-08-07 2010-06-01 Zymogenetics, Llc Method of using IL-29 cysteine mutant to treat hepatitis C and hepatitis B
US7351689B2 (en) * 2004-07-29 2008-04-01 Zymogenetics, Inc. Use of IL-28 and IL-29 to treat cancer and autoimmune disorders
US20110165121A1 (en) * 2008-06-05 2011-07-07 Hausman Diana F Use of pegylated type iii interferons for the treatment of hepatitis c

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZALIPSKY, S.: "Chemistry of polyethylene glycol conjugates with biologically active molecules", ADV. DRUG. DELIV. REV., vol. 16, no. 2-3, 1995, pages 157 - 182 *

Similar Documents

Publication Publication Date Title
US8980245B2 (en) PEG-interferon λ1 conjugates and methods of treating viral infections
TWI364295B (en) Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
TW570802B (en) Improved interferon polymer conjugates
US20060029573A1 (en) Pegylated interferon alpha-1b
CZ298597B6 (cs) Zpusob postupné vazby polyethylenglykolových skupin na polypeptid
BG62273B1 (bg) Конюгати на интерферон
EA008866B1 (ru) ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
Nojima et al. Development of poly (ethylene glycol) conjugated lactoferrin for oral administration
KR20100082774A (ko) 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ｂ, 이의 제조 방법 및 용도
US20140315826A1 (en) Polymeric conjugates of c-1 inhibitors
TW524806B (en) Chemical modification of proteins to improve biocompatibility and bioactivity
CA2846092A1 (fr) Conjugues lambda 1 d'interferon peg
WO2012011836A1 (fr) Nouveau conjugué stable de polyéthylène glycol-interféron alpha, représenté par un isomère positionnel
US20110280826A1 (en) Y-shaped polyethylene glycol modified g-csf, the preparation and use thereof
CN103923209B (zh) 一种Lambda干扰素突变体及聚乙二醇衍生物
Kim et al. Bioimaging of Hyaluronate–Interferon α Conjugates Using a Non-Interfering Zwitterionic Fluorophore
EP2196475B1 (fr) INTERFERON ALPHA 2a MODIFIÉ PAR POLYETHYLÈNEGLYCOL, SON PROCESSUS DE SYNTHÈSE ET SON APPLICATION
KR101521674B1 (ko) 이중-가닥 폴리에틸렌 글리콜-수식된 성장 호르몬, 이의 제조 방법 및 용도
CN105085658B (zh) 一种白细胞介素29突变体及聚乙二醇衍生物
CN102584979B (zh) PEG化干扰素λ
WO2013029062A1 (fr) Conjugués lambda 1 d'interféron peg, leurs procédés de préparation, compositions pharmaceutiques contenant ces conjugués et leurs procédés de fabrication
CN105085657A (zh) 一种干扰素突变体及聚乙二醇衍生物
AU2013226944B2 (en) Inhibitory agent for body cavity fluid accumulation
CN101385858B (zh) 纯化的peg化人生长激素缀合物及其药物制剂
Rachmawati et al. Evaluation of adverse effects of mutein forms of recombinant human interferon alpha-2b in female Swiss Webster mice

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11871200

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11871200

Country of ref document: EP

Kind code of ref document: A1